Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Perrone

Showing results (121-130 of 184) with videos related to

Pageof 19
Sort By:
Anticancer Research|March 26, 2002
Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II studyC Gridelli, C Curcio, R V Iaffaioli, et al.
ESMO Open|April 5, 2021
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?N Silvestris, M Di Maio, A Russo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2014
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylationF Pietrantonio, F Perrone, F de Braud, et al.
British Journal of Cancer|May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) groupS Pignata, G Scambia, C Pisano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2008
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patientsF Perrone, A Lampis, M Orsenigo, et al.
ESMO Open|June 11, 2025
Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)M Del Re, R Roncato, A Argentiero, et al.
Drugs of Today (Barcelona, Spain : 1998)|October 23, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumorsA Morabito, M C Piccirillo, R Costanzo, et al.
British Journal of Cancer|August 23, 2000
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin InvestigatorsC Gridelli, L Frontini, F Perrone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trialA Necchi, S Lo Vullo, P Giannatempo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2011
Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patientsL Licitra, F Perrone, E Tamborini, et al.
Pageof 19

Showing results (121-130 of 184) with videos related to

Sort By:
Pageof 19
Anticancer Research|March 26, 2002
Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II studyC Gridelli, C Curcio, R V Iaffaioli, et al.
ESMO Open|April 5, 2021
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?N Silvestris, M Di Maio, A Russo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2014
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylationF Pietrantonio, F Perrone, F de Braud, et al.
British Journal of Cancer|May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) groupS Pignata, G Scambia, C Pisano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2008
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patientsF Perrone, A Lampis, M Orsenigo, et al.
ESMO Open|June 11, 2025
Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)M Del Re, R Roncato, A Argentiero, et al.
Drugs of Today (Barcelona, Spain : 1998)|October 23, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumorsA Morabito, M C Piccirillo, R Costanzo, et al.
British Journal of Cancer|August 23, 2000
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin InvestigatorsC Gridelli, L Frontini, F Perrone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trialA Necchi, S Lo Vullo, P Giannatempo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2011
Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patientsL Licitra, F Perrone, E Tamborini, et al.
Pageof 19